Insulin Resistance

Insulin Resistance

Insulin resistance is a metabolic state in which the body’s cells — particularly those in skeletal muscle, the liver, and adipose tissue — exhibit a diminished response to the hormone insulin. Under normal conditions, insulin facilitates the uptake of glucose from the bloodstream into cells, where it is used for energy or stored as glycogen. When cells become insulin resistant, higher concentrations of circulating insulin are required to achieve the same glucose-lowering effect, leading to compensatory hyperinsulinemia. Over time, if the pancreatic beta cells cannot sustain this elevated insulin output, blood glucose levels rise, progressing from prediabetes to overt type 2 diabetes.

Insulin resistance is strongly linked to excess visceral adiposity and is considered a central driver of metabolic syndrome. Visceral fat tissue releases inflammatory cytokines and free fatty acids that interfere with insulin signaling pathways in peripheral tissues. This creates a self-reinforcing cycle: insulin resistance promotes further fat storage, particularly in the abdominal region, which in turn worsens insulin resistance. Breaking this cycle is a primary goal of pharmacological interventions targeting obesity and type 2 diabetes.

Retatrutide addresses insulin resistance through multiple complementary mechanisms. Its GLP-1 and GIP receptor agonist activity directly enhances insulin secretion and sensitivity, while the glucagon receptor component promotes hepatic fat oxidation and energy expenditure, reducing the visceral fat burden that drives insulin resistance. In Phase 2 clinical trials, retatrutide treatment resulted in significant improvements in markers of insulin sensitivity alongside dramatic weight loss, suggesting that the triple agonist approach may be particularly effective at reversing the metabolic derangements associated with insulin resistance.